ESR1 and breast cancer: Although the compounds were designed to target delivery of the cytotoxic ferrocene group to cells overexpressing estrogen receptors, they showed significant in vitro activity against both hormone–dependent MC–7 cells and triple–negative MDA–MB–23 breast cancer cells (IC50 = 0.7 μM and IC50 = 0.6 for 1, respectively).